Marc Owen - Smith Nephew Non-Executive Director

SNNUF Stock  USD 12.07  0.20  1.63%   

Director

Mr. Marc E. Owen is NonExecutive Independent Director of the Company., effective October 1, 2017. He is a Member of the Audit Committee in October 2017 and Member of the Compliance Culture Committee in March 2018. He will be appointed chair of the Compliance Culture Committee in April 2019. Career and experience Marc graduated from Oxford University with a BA and BCL in Law. In 1984 he was called to the Bar, following four years at Corporationrations Christi College Cambridge as a fellow and director of studies in law. He decided upon a corporate career and undertook an MBA at Stanford University. Marc commenced his healthcare and technology career at McKinsey Company where he progressed to senior partner and eventually a founding partner of McKinseys Business Technology Office. In September 2001, Marc joined McKesson Corporation and served as Executive Vice President and member of the Executive Committee. He delivered strategic objectives and led over 40 acquisitions and divestments over a 10year period. In late 2011 he headed Mckesson Speciality Health, which operates over 130 cancer centres across the US and provides services including market intelligence, supply chain services, patient access to therapy, provider and patient engagement and clinical trial support. His final executive role came in 2014 where he was appointed Chair of the European Management Board at Celesio AG. He retired in March 2017 once he had improved operations, set the strategy and recruited his successor. Skills and competencies Marc is a proven leader with an astute, strategic vision, capable of building significant international healthcare businesses. He has strong commercial healthcare expertise which the Board values deeply and makes him ideally placed to Chair the Compliance Culture Committee. since 2017.
Age 59
Tenure 7 years
Professional MarksMBA
Phone44 1923 477 100
Webhttps://www.smith-nephew.com

Smith Nephew Management Efficiency

The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.71 B in total debt with debt to equity ratio (D/E) of 0.54, which is about average as compared to similar companies. Smith Nephew plc has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Smith Nephew until it has trouble settling it off, either with new capital or with free cash flow. So, Smith Nephew's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Smith Nephew plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Smith to invest in growth at high rates of return. When we think about Smith Nephew's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

David HoffmeisterGlaukos Corp
66
Donald SpenceInteger Holdings Corp
67
Michael JacobiSonova Holding AG
64
Harald RufOrthopediatrics Corp
64
Filippo PasseriniInteger Holdings Corp
63
Craig SwandalApyx Medical
56
John AndresApyx Medical
59
Randall HoganMedtronic PLC
64
Brian ConcannonCONMED
62
Francesco BianchiLivaNova PLC
60
Austin AdamsParagon 28
71
Alfred NovakLivaNova PLC
70
Jo GoldenCONMED
69
Pamela BaileyInteger Holdings Corp
72
James LenehanMedtronic PLC
71
Kristina WrightParagon 28
47
Michael LeavittMedtronic PLC
69
John WorkmanCONMED
69
Minnie BaylorHenryApyx Medical
N/A
Guido NeelsAxogen Inc
69
Kendall PowellMedtronic PLC
66
Smith Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 18000 people. Smith Nephew plc [SNNUF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Smith Nephew plc Leadership Team

Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director
Michael Friedman, Non-Executive Independent Director
Diogo MoreiraRato, President - Europe and Canada
Alison Parkes, Chief Officer
Skip Kiil, President - Orthopedics
Erik Engstrom, Non-Executive Director
Deepak Nath, CEO Director
Matthew Stober, President - Global Operations
Marc Owen, Non-Executive Director
AnneFrancoise Nesmes, CFO Director
Helen Barraclough, Company Counsel
Rodrigo Bianchi, President IRAMEA
Brian Larcombe, Senior Independent Non-Executive Director
Elga Lohler, Chief Human Resource Officer
Bradley Cannon, Sports Orthopaedics
Gunthorp Oie, IR Contact Officer
Roland Diggelmann, Non-Executive Director
Helen Maye, Chief Human Resources Officer
Vinita Bali, Non-Executive Director
Simon Fraser, President - Advanced Wound Management
Massimiliano Colella, President Europe - Middle East and Africa
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee
Graham Baker, CFO, Executive Director
Cathy ORourke, Chief Legal and Compliance Officer
Roberto Quarta, Non-Executive Independent Chairman of the Board
Joe Metzger, VP Communications
Cyrille Petit, Chief Corporate Development Officer
Julie Brown, CFO, Director and Member of Disclosures Committee
Glenn Warner, President - Advanced Wound Management
Robin Freestone, Non-Executive Director
Paul Connolly, Pres Operations
Virginia Bottomley, Non-Executive Independent Director
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs
Angie Risley, Non-Executive Director
Mark Gladwell, President - Global Operations
Andrew Swift, VP Relations
Vasant Padmanabhan, President - Research & Development
Michael Frazzette, President - Advanced Surgical Devices
Joseph Papa, Non-Executive Independent Director
Ingeborg Oie, VP, Investor Relations
Susan Swabey, Company Secretary
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer
Philip Cowdy, Chief Officer
Gordon Howe, President of Global Operations
John Campo, Chief Legal Officer
Brad Cannon, President Europe and Canada
Ian Barlow, Non-Executive Independent Director
Catheryn ORourke, Chief Legal Officer

Smith Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Smith Pink Sheet analysis

When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.